Unknown

Dataset Information

Subjects' views of obligations to ensure post-trial access to drugs, care and information: qualitative results from the Experiences of Participants in Clinical Trials (EPIC) study.


ABSTRACT:

Objectives

To report the attitudes and opinions of subjects in US clinical trials about whether or not, and why, they should receive post-trial access (PTA) to the trial drug, care and information.

Design

Focus groups, short self-administered questionnaires.

Setting

Boston, Dallas, Detroit, Oklahoma City.

Participants

Current and recent subjects in clinical trials, primarily for chronic diseases.

Results

93 individuals participated in 10 focus groups. Many thought researchers, sponsors, health insurers and others share obligations to facilitate PTA to the trial drug, if it benefited the subject, or to a therapeutic equivalent. Some thought PTA obligations include providing transition care (referrals to non-trial physicians or other trials, limited follow

SUBMITTER: Sofaer N 

PROVIDER: S-EPMC3044680 | biostudies-literature | 2009 Mar

REPOSITORIES: biostudies-literature